Using CRISPR to Defeat Friedreich’s Ataxia: A...
Jul. 6, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Capsida Biotherapeutics
Main focus: Gene editing for the treatment of central nervous system (CNS) disorders
Company stage: Pre-clinical
Diseases: ALS and Friedreich’s ataxia
Genome editing tool: Delivery using engineered adeno-associated virus (AAV)
Funding stage: Private
Location: Newbury Park, CA, USA
Website: https://capsida.com/
Partners: CRISPR Therapeutics
Capsida Biotherapeutics is developing adeno-associated viral (AAV) vectors for novel gene therapies. The company's involvement in the gene editing space comes from the collaboration with CRISPR Therapeutics. The two companies are developing novel in vivo gene-editing therapies for familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia.
